Evidence map›Paper›PMID 40324788›Full record

ArticlePediatrics2025

Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024.

Stephanie A Irving, Bradley Crane, Eric S Weintraub, Suchita A Patel, Hilda Razzaghi, Matthew F Daley, Brian Dixon, James G Donahue, Candace C Fuller, Sharon Fuller and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Stephanie A IrvingKaiser Permanente Center for Health Research, Portland, Oregon.
Bradley CraneKaiser Permanente Center for Health Research, Portland, Oregon.
Eric S WeintraubImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Suchita A PatelImmunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Hilda RazzaghiImmunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Matthew F DaleyInstitute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
Brian DixonFairbanks School of Public Health, Indiana University Indianapolis, Indianapolis, Indiana.
James G DonahueMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Candace C FullerHarvard Pilgrim Health Care Institute, Boston, Massachusetts.
Sharon FullerKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Darios GetahunDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Sungching C GlennDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Simon J HambidgeAmbulatory Care Services, Denver Health, Denver, Colorado.
Lisa A JacksonKaiser Permanente Washington Health Research Institute, Seattle, Washington.
Karen B JacobsonKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
Elyse O KharbandaHealthPartners Institute, Pregnancy and Child Research Center, Minneapolis, Minnesota.
Judith C MaroHarvard Pilgrim Health Care Institute, Boston, Massachusetts.
Sean T O'LearyOCHIN, Inc, Portland, Oregon.
Teresa SchmidtOCHIN, Inc, Portland, Oregon.
Katharine SznajderMid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Washington, DC.
Nancy S WeinfieldMid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Washington, DC.
Joshua T B WilliamsAmbulatory Care Services, Denver Health, Denver, Colorado.
Ousseny ZerboKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
Allison L NalewayKaiser Permanente Center for Health Research, Portland, Oregon.

Funding

CDC HHS 75D30122D15425
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn 2023, the Advisory Committee on Immunization Practices recommended either Abrysvo, a vaccine administered during pregnancy, or nirsevimab, a monoclonal antibody administered to infants after birth, to protect infants from respiratory syncytial virus (RSV). Our objective was to assess the proportion of infants immunized against RSV through antenatal RSV vaccination or receipt of nirsevimab among linked pregnancy-infant dyads.

methodsUsing data from 10 Vaccine Safety Datalink health systems and a validated algorithm, we identified pregnant women aged 12 to 55 years with a live birth of 32 weeks' gestation or more from September 22, 2023, through March 31, 2024. We identified RSV vaccination using electronic health records supplemented with immunization information system (registry) data. Among infants from eligible pregnancies, we identified nirsevimab administered through March 31, 2024. We assessed infant RSV immunization, defined as exposure to antenatal RSV vaccination or receipt of nirsevimab, stratified by race and ethnicity, age, and birth month.

resultsA total of 36 949 eligible infants were included from 43 722 pregnancies. Overall, 72% of infants were immunized against RSV; estimates were highest among infants born to non-Hispanic (NH) Asian mothers (84%). Disparities were identified by race, with 60% coverage among infants born to NH Black or NH Middle Eastern or North African mothers. Coverage was 59% to 78% by birth month, with nirsevimab more commonly administered to infants born earlier in the season.

conclusionsIn this population of infants, 72% were immunized against RSV. Although overall coverage was high, disparities in immunization by race and ethnicity are a call to action.

Indexed as

Antibodies, Monoclonal, HumanizedRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccination CoverageAdolescentAdultChildDatabases, FactualFemaleHumansInfantInfant, NewbornMaleMiddle AgedPregnancyUnited StatesAntibodies, Monoclonal, HumanizedRespiratory Syncytial Virus Vaccines

Identifiers

PMID40324788
PMCPMC12981371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.